Tanaya Shree, MD, PhD, on DLBCL Survivors: Long-Term Effects

2017 ASH Annual Meeting

Tanaya Shree, MD, PhD, of Stanford University Medical Center, discusses findings from a large population-based study suggesting lasting effects of lymphoma and its treatments: an increased incidence of autoimmune and infectious diseases (Abstract 198).



Related Videos

Leukemia

John F. Seymour, MBBS, PhD, on CLL: Results From the MURANO Study

John F. Seymour, MBBS, PhD, of the Peter MacCallum Cancer Centre, discusses an interim analysis of venetoclax plus rituximab vs bendamustine plus rituximab in patients with relapse...

Multiple Myeloma

Maria-Victoria Mateos, MD, PhD, on Multiple Myeloma: Results From the ALCYONE Trial

Maria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, discusses phase III study findings on daratumumab plus bortezomib, melphalan, and prednisone vs bortezomib,...

Lymphoma

Joseph M. Connors, MD, on Untreated Hodgkin Lymphoma: Results From the ECHELON-1 Trial

Joseph M. Connors, MD, of the British Columbia Cancer Agency, discusses study findings on a new front-line option: brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazin...

Lymphoma

Mark J. Roschewski, MD, on Burkitt Lymphoma: Clinical Trial Results on DA-EPOCH-R

Mark J. Roschewski, MD, of the National Cancer Institute, discusses phase II study findings that showed DA-EPOCH-R cures most adult patients with Burkitt lymphoma, irrespective of ...

Lymphoma

Andrew D. Zelenetz, MD, PhD, and Stephen J. Schuster, MD, on DLBCL: Results of the JULIET Trial

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephen J. Schuster, MD, of the Abramson Cancer Center, University of Pennsylvania, dis...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.